Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.

PMID:
30420245
2.

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.

Wijbrandts CA, Tak PP.

Mayo Clin Proc. 2017 Jul;92(7):1129-1143. doi: 10.1016/j.mayocp.2017.05.009. Review.

3.

MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

Choi IY, Gerlag DM, Herenius MJ, Thurlings RM, Wijbrandts CA, Foell D, Vogl T, Roth J, Tak PP, Holzinger D.

Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.

PMID:
24297376
4.

Local synovial engagement of angiogenic TIE-2 is associated with the development of persistent erosive rheumatoid arthritis in patients with early arthritis.

van de Sande MG, de Launay D, de Hair MJ, García S, van de Sande GP, Wijbrandts CA, Gerlag DM, Reedquist KA, Tak PP.

Arthritis Rheum. 2013 Dec;65(12):3073-83. doi: 10.1002/art.38128.

5.

Images in clinical medicine. Pain in the thumb related to disease in the lung.

Wijbrandts CA, van Schaardenburg D.

N Engl J Med. 2013 May 2;368(18):1731. doi: 10.1056/NEJMicm1212346. No abstract available.

6.

Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation.

Herenius MM, Oliveira AS, Wijbrandts CA, Gerlag DM, Tak PP, Lebre MC.

PLoS One. 2013;8(2):e57802. doi: 10.1371/journal.pone.0057802. Epub 2013 Feb 27.

7.

The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria.

van de Sande MG, de Hair MJ, Schuller Y, van de Sande GP, Wijbrandts CA, Dinant HJ, Gerlag DM, Tak PP.

PLoS One. 2012;7(5):e36668. doi: 10.1371/journal.pone.0036668. Epub 2012 May 4.

8.

Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis.

Klaasen R, Herenius MM, Wijbrandts CA, de Jager W, van Tuyl LH, Nurmohamed MT, Prakken BJ, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Sep;71(9):1510-6. doi: 10.1136/annrheumdis-2011-200646. Epub 2012 Mar 22.

9.

Characteristics of synovial inflammation in early arthritis analysed by pixel-by-pixel time-intensity curve shape analysis.

van de Sande MG, van der Leij C, Lavini C, Wijbrandts CA, Maas M, Tak PP.

Rheumatology (Oxford). 2012 Jul;51(7):1240-5. doi: 10.1093/rheumatology/kes011. Epub 2012 Feb 28.

PMID:
22375037
10.

Synovial synoviolin in relation to response to TNF blockade in patients with rheumatoid arthritis and psoriatic arthritis.

Klaasen R, Wijbrandts CA, van Kuijk AW, Pots D, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Jul;71(7):1260-1. doi: 10.1136/annrheumdis-2011-200741. Epub 2012 Feb 17. No abstract available. Erratum in: Ann Rheum Dis. 2012 Sep;71(9):1592.

PMID:
22345123
11.

Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets.

de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, Wijbrandts CA, van Baarsen LG, Gerlag DM, Tak PP, Reedquist KA.

Ann Rheum Dis. 2012 Mar;71(3):415-23. doi: 10.1136/ard.2010.143529. Epub 2011 Sep 27.

12.

The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.

Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, Out TA, de Nooijer MJ, Baeten D, Tak PP.

Rheumatology (Oxford). 2011 Aug;50(8):1487-93. doi: 10.1093/rheumatology/ker010. Epub 2011 Mar 30.

PMID:
21454308
13.

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ.

Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209.

14.

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab.

Herenius MM, Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, Wouters D, Izmailova ES, Gerlag DM, van Eck-Smit BL, Tak PP.

Ann Rheum Dis. 2011 Jun;70(6):1160-2. doi: 10.1136/ard.2010.141549. Epub 2011 Feb 22.

15.

Body mass index and clinical response to infliximab in rheumatoid arthritis.

Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP.

Arthritis Rheum. 2011 Feb;63(2):359-64. doi: 10.1002/art.30136.

16.

Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.

Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, Crusius JB, Dijkmans BA, Tak PP, Aarden L, Wolbink GJ.

Arthritis Res Ther. 2010;12(6):R221. doi: 10.1186/ar3208. Epub 2010 Dec 27.

17.

Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?

van de Sande MG, Thurlings RM, Boumans MJ, Wijbrandts CA, Modesti MG, Gerlag DM, Tak PP.

Ann Rheum Dis. 2011 Apr;70(4):700-3. doi: 10.1136/ard.2010.139287. Epub 2010 Dec 20.

PMID:
21173012
18.

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.

Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP.

PLoS One. 2010 Jun 25;5(6):e11310. doi: 10.1371/journal.pone.0011310.

19.

Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.

van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2010 Dec;11(8):622-9. doi: 10.1038/gene.2010.34. Epub 2010 Jun 17.

PMID:
20555356
20.

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood.

van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, Verweij CL.

Arthritis Rheum. 2010 Jun;62(6):1602-7. doi: 10.1002/art.27415.

21.

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL.

Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912. Epub 2010 Jan 22.

22.

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw Kraan TC, Verweij CL, Tak PP, Baeten DL.

Rheumatology (Oxford). 2010 Jan;49(1):156-66. doi: 10.1093/rheumatology/kep345. Epub 2009 Nov 23. Erratum in: Rheumatology (Oxford). 2014 Apr;53(4):770. van der Pouw, Tineke Kraan [corrected to van der Pouw Kraan, Tineke C T M].

PMID:
19933783
23.

Monocyte scintigraphy in rheumatoid arthritis: the dynamics of monocyte migration in immune-mediated inflammatory disease.

Thurlings RM, Wijbrandts CA, Bennink RJ, Dohmen SE, Voermans C, Wouters D, Izmailova ES, Gerlag DM, van Eck-Smit BL, Tak PP.

PLoS One. 2009 Nov 17;4(11):e7865. doi: 10.1371/journal.pone.0007865.

24.

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.

25.

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Wolbink GJ, de Vries N, Tak PP, Dijkmans BA, Crusius JB, van der Horst-Bruinsma IE.

Arthritis Rheum. 2009 Aug;60(8):2541-2. doi: 10.1002/art.24709. No abstract available.

26.

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2010 May;69(5):817-21. doi: 10.1136/ard.2009.112847. Epub 2009 Jul 5.

PMID:
19581278
27.

Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation.

Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, Dijkmans BA, Wijbrandts CA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MH.

Scand J Rheumatol. 2009;38(4):246-50. doi: 10.1080/03009740902748264.

PMID:
19337948
28.

TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.

van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP.

Ann Rheum Dis. 2010 Jan;69(1):301-4. doi: 10.1136/ard.2008.090548.

29.

Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients.

Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh Weerman MA, Smeets TJ, Vervoordeldonk MJ, Baeten D, Tak PP.

Arthritis Rheum. 2008 Nov;58(11):3330-9. doi: 10.1002/art.23989.

30.

Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis.

Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP.

Ann Rheum Dis. 2009 Aug;68(8):1316-21. doi: 10.1136/ard.2007.086728. Epub 2008 Aug 22.

31.

Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.

Cantaert T, De Rycke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, Vandooren B, Veys EM, Richel D, Tak PP, Crow MK, Baeten D.

Ann Rheum Dis. 2009 Jun;68(6):1022-9. doi: 10.1136/ard.2008.093724. Epub 2008 Jul 14.

32.

Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.

Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP.

Arthritis Rheum. 2008 Jun;58(6):1582-9. doi: 10.1002/art.23505.

33.

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.

Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP.

Ann Rheum Dis. 2009 Mar;68(3):373-6. doi: 10.1136/ard.2008.091611. Epub 2008 Apr 13.

34.

Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis.

Straub RH, Pongratz G, Cutolo M, Wijbrandts CA, Baeten D, Fleck M, Atzeni F, Grunke M, Kalden JR, Schölmerich J, Lorenz HM, Tak PP, Sarzi-Puttini P.

Arthritis Rheum. 2008 Apr;58(4):976-84. doi: 10.1002/art.23385.

35.

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.

Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BA, Tak PP.

Ann Rheum Dis. 2008 Aug;67(8):1139-44. Epub 2007 Nov 29.

36.

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.

Ann Rheum Dis. 2008 Apr;67(4):563-6. Epub 2007 Nov 27.

PMID:
18042642
37.

Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker.

Wijbrandts CA, Vergunst CE, Haringman JJ, Gerlag DM, Smeets TJ, Tak PP.

Arthritis Rheum. 2007 Nov;56(11):3869-71. No abstract available.

38.

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.

Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP.

Ann Rheum Dis. 2008 Jul;67(7):917-25. Epub 2007 Oct 26.

39.

Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients.

van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2008 Jan;9(1):16-22. Epub 2007 Oct 11.

PMID:
17928867
40.

The Academic Medical Center Linear Disability Score item bank: psychometric properties of a new generic disability measure in rheumatoid arthritis.

Weisscher N, Wijbrandts CA, de Haan R, Glas CA, Vermeulen M, Tak PP.

J Rheumatol. 2007 Jun;34(6):1222-8.

PMID:
17552054
41.

Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers.

Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, Fitzgerald O, Kirkham BW, McInnes IB, Smith M, Ulfgren AK, Veale DJ, Tak PP.

J Rheumatol. 2007 Mar;34(3):620-2.

PMID:
17343309
42.

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.

Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.

Arthritis Rheum. 2007 Mar;56(3):772-8.

43.

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.

Ann Rheum Dis. 2007 Jul;66(7):921-6. Epub 2007 Feb 14.

44.

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL.

Ann Rheum Dis. 2007 Aug;66(8):1008-14. Epub 2007 Jan 12.

45.

CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells.

Remans PH, Wijbrandts CA, Sanders ME, Toes RE, Breedveld FC, Tak PP, van Laar JM, Reedquist KA.

Arthritis Rheum. 2006 Oct;54(10):3135-43.

Supplemental Content

Loading ...
Support Center